Rituximab Market size was over USD 4.03 billion in 2024 and is anticipated to cross USD 27.13 billion by 2037, witnessing more than 15.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of rituximab is estimated at USD 5.11 billion.
The increasing incidences of non-Hodgkin’s lymphoma (NHL) are expected to boost the market growth of rituximab. As per the American Cancer Society, NHL is one of the most common diseases in the USA. Around 77,200 cases were registered in 2020 in the US, the incidences are anticipated to grow rapidly due to the rising cases of cancer in the region.
In case of an autoimmune disease, the immune system attacks the healthy cells of the body. Thus, the rising prevalence of autoimmune diseases is likely to accelerate the growth of the rituximab market. According to the reports by University of Oxford, about 22 million are affected by autoimmune diseases yearly. These factors are bolstering the market growth of rituximab.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
15.80% |
|
Base Year Market Size (2024) |
USD 4.03 billion |
|
Forecast Year Market Size (2037) |
USD 27.13 billion |
|
Regional Scope |
|
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The hospital pharmacies segment in the rituximab market is expected to garner the largest revenue during the forecast period. Due to the growing use of rituximab for cancer therapy in hospitals, the hospital pharmacies segment is expected to account for a total market share of 39.7% by 2037. The dominant position of the sector is expected to be achieved during the forecast period by rising healthcare spending around the world, increased awareness levels for patients, and availability of superior hospital infrastructure in high-income countries.
Application (Blood Cancer, Rheumatoid Arthritis, Wegener’s Granulomatosis)
The blood cancer segment is expected to hold 24% share of the global rituximab market by 2037. Nearly every 3 minutes, one person in the US is diagnosed with blood cancer. Leukaemia was the sixth most frequent cause of cancer deaths in men from 2013 to 2017 and the seventh most frequent cause in women in the US. Also, the increased funding and investment in healthcare mostly in cancer is driving the growth of the market. The cases associated with blood cancer are expected to increase in the upcoming years due to lifestyle factors which will significantly boost the market growth of rituximab.
Our in-depth analysis of the global market includes the following segments:
|
Distribution Channel |
|
|
Application |
|
North American Market Forecast
North America industry is anticipated to dominate majority revenue share of 45% by 2037, In addition, market growth is expected to be fuelled by increased government spending on cancer research as well as the presence of major pharmaceutical companies such as Pfizer Inc., Amgen Inc., and Merck & Co.
APAC Market Statistics
The Asia Pacific region is expected to hold the second-largest position in the rituximab market. In view of rising disposable incomes, availability of a large patient population for monoclonal antibody cancer treatments, and increased focus on healthcare, the Asia Pacific region is expected to show the highest growth rate during the forecast period at 12.1%. As well as providing investment opportunities in clinical research, countries such as India and China are expected to have a positive impact on the R&D prospects for monoclonal antibodies.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?